QNCX Investor Conference discussion. September 9th.

{"summary": "Author gives a bullish case for QNCX based on LAM-001's differentiated once-daily lung transplant treatment, surgeon endorsement, funded runway to 2028, and completed dilution.", "reason": "The author provides a directional thesis based on specific product efficacy, clinical data, and financial runway.", "ideas": [{"symbol": "QNCX", "direction": "long", "thesis": "The author argues QNCX's LAM-001 addresses an unmet need in reaching deep lung tissue with a once-daily formulation requiring no medical supervision, and has been vocally endorsed by top US transplant surgeons as something needed for over a decade. They cite improved lung function data post-transplant, a runway financed until 2028, and completed dilution as supporting a potential move toward roughly $185 versus downside around $20. The main stated risk is downside to $20, and they suggest layering in as a starting position.", "thesis_short": "QNCX LAM-001 lung transplant upside to $185", "quote": "Based on the unmet needs vs outcome vs efficiency of reaching the deep tissue of the lungs, while others seem to lack this.", "confidence": 0.7, "sentiment": 0.8, "timeframe": "1 year estimate"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}